{
  "report_rows": [
    {
      "kpi": "Q2 2026 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$7.72 vs. cons $7.57",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Cigna Healthcare MCR",
      "prediction": "BEAT",
      "answer": "pred ~83.9% vs. cons 84.8%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Specialty and Care Services pretax adjusted earnings",
      "prediction": "BEAT",
      "answer": "pred ~$1.04B vs. cons $1.01B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted EPS floor",
      "prediction": "BETTER",
      "answer": "guide ~$30.50 vs. cons $30.39 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Cigna Healthcare pretax adjusted earnings floor",
      "prediction": "BETTER",
      "answer": "guide ~$4.60B vs. cons $4.58B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Evernorth pretax adjusted earnings floor",
      "prediction": "LOWER",
      "answer": "guide ~$6.90B vs. cons $6.92B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Pharmacy Benefit Services client retention",
      "prediction": "UNCHANGED",
      "answer": "guide ~95% vs. cons 95% (2027 selling season)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.1,
  "day5_path": "FADE",
  "day5_rationale": "A favorable MCR and Specialty-led Q2 beat should drive the initial gain, but a ~$30.50 FY2026 floor implies roughly $14.99 of second-half EPS versus prior consensus near $15.03, an implicit out-period cut as Signature investment ramps; estimates should therefore rise less than the headline beat and partially fade.",
  "day5_confidence": "MEDIUM"
}